Two strategies to interrogate the insulin growth factor 1 receptor ( IGF-1R ) pathway were investigated : vertical inhibition with dalotuzumab and MK-2206 or ridaforolimus to potentiate PI3K pathway targeting and horizontal cross-talk inhibition with dalotuzumab and MK-0752 to exert effects against cellular proliferation , angiogenesis , and stem cell propagation .